November 11th 2024
Findings from the CAPELLA study reveal virologic suppression and a safety profile for multidrug-resistant HIV-1.
October 28th 2024
All HIV Patients Should be Tested for Tuberculosis in High-Burden Areas
April 18th 2022The meta-analysis included 6 studies, of which 5 were conducted in sub-Saharan Africa, showed that the diagnostic accuracy for Xpert testing was similar to the former symptom screening and rapid test format.
Read More
Label Update for Cabotegravir and Rilpivirine Long-Acting HIV Treatment
March 24th 2022With FDA Approval, the oral lead-in for the cabotegravir and rilpivirine long-acting HIV treatment (Cabenuva) is now optional. Clinical trial data showed similar safety and efficacy profiles for initiating the therapy with or without the oral lead-in.
Read More
“Ramp Up the Resources”: Increased Effort and Funding Needed to End HIV
March 23rd 2022Congress’s spending bill allocated drastically less funding for HIV testing, prevention, and treatment than previously promised. Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, explains why it is so vital to continue the fight against HIV.
Read More
Seeking Solutions for Endocarditis in People Who Inject Drugs
March 7th 2022“People don’t recognize that at least 1 in 5 of the deaths from opioids may result from endocarditis,” said National Institute of Drug Abuse (NIDA) director Dr. Nora Volkow, adding that endocarditis is “100% preventable.”
Read More
Age-Related Comorbidities and Quality-of-Life Issues in Patients Living With HIV
February 25th 2022For people living with HIV, age-related comorbidities, such as obesity and diabetes, as well as quality-of-life issues remain challenges. Our Peer Exchange panel discusses clinical approaches for this patient population and trying to keep them in good health.
Read More